Dr Reddys launches Sapropterin Dihydrochloride Powder for Oral Solution in US
Hyderabad: Drug major, Dr. Reddy's Laboratories Ltd., today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg in US.
The product is a therapeutic equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA).
Sapropterin dihydrochloride is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet.
"We are pleased to launch this generic version of Sapropterin Dihydrochloride Powder for Oral Solution, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories.
"At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease."
Dr. Reddy's Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.
Read also: Dr Reddy's Labs launches Lansoprazole DR Orally Disintegrating Tablets in US
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Read also: Dr Reddy's Labs launches generic Prolixin tablets in US
